Abbott Gmbh & Co Kg

Abbott Laboratories Corporation

Abbvie Deutschland Gmbh and Co Kg

Matthias Mayrer

Liliane Unger

Andreas Haupt

Wilfried Martin Braje

Karla Drescher

Sean Colm Turner

Udo Lange

Karsten M Wicke

Mario Mezler

Wolfgang Wernet

Min Zhang

Anton Bespalov

Andrea Hager-Wernet, Legal Representative

Alfred Hahn, Legal Representative

Ana Lucia Jongen-Relo

Thomas Schultz

The present invention relates to compounds of formula (I) wherein A is C-C-alkyl, C-C-haloalkyl, C-C-hydroxyalkyl, C-C-alkenyl, C-C-halo-alkenyl, C-C-cycloalkyl, aryl-C-C-alkyl, aryl-C-C-alkenyl, aryl or hetaryl;is a single or double bond; Xand Xare N, CR, NRor CRR; R, Rand Rare H, halogen, CN, NO, C-C-alkyl, C-C-alkoxy, C-C-alkylcarbonyl, etc. or two geminal radicals Rand Rtogether with the carbon atom to which they are bound may form a carbonyl group or a 3- to 6-membered carbocyclic or heterocyclic spiro-annulated ring; Ris hydrogen, C-C-alkyl, C-C-alkylcarbonyl, C-C-haloalkyl, etc.; or two vicinal radicals R, R, Ror Rtogether with Xand Xform a five- or six-membered carbocyclic or heterocyclic fused ring; Y, Yand Yare N or CR; Ris H, halogen, CN, NO, C-C-alkyl, C-C-alkoxy, C-C-alkylcarbonyl, C-C-haloalkyl, etc.; wherein a maximum of 3 of the radicals X, X, Y, Yand Yare selected from NRand N; Ris hydrogen, C-C-alkyl, C-C-hydroxyalkyl, C-C-haloalkyl, etc.; Ris C-C-alkyl or C-C-haloalkyl; n is 0, 1 or 2; physiologically tolerated acid addition salts and the N-oxides thereof, pharmaceutical composition comprising them, a method for treating medical disorders selected from diseases of the central nervous system, addiction diseases or obesity, said method comprising administering an effective amount of such compounds to a subject in need and the use of such a compound for preparing a pharmaceutical compositions.

[object Object]

The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HTreceptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X', Y, Q, R, R, R, R, R, m, n, p, q, R, R, X and Ar are as defined in claim. 

The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HTreceptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X', Y, Q, R, R, R, R, R, m, n, p, q, R, R, X and Ar are as defined in claim 1. 

The present invention relates to novel quinoline compounds. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HTreceptor. wherein 

Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I' and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HTreceptor. 

Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

Growing community of inventors

Ludwigshafen, Germany

Matthias Mayrer